The AZD-9291 and GDC-0084 combination therapy inhibited the proliferation of GBM cells by simultaneously blocking the EGFR/ERK and PI3K/AKT/mTOR signaling pathways, thereby blocking cell cycle progression. Here, MTOR is linked to glioblastoma.